Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions are flooding the market. From cardiology and imaging to oncology and primary care, clinicians are being asked to evaluate algorithms that promise earlier detection, better accuracy, and more efficient care. Many of these tools are technically impressive. Some are FDA-cleared. A few even come with early clinical data. Yet only a relatively small number have become part of routine clinical practice.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Related Articles
Anumana wins FDA clearance for ECG-AI algorithm
Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.{post_date: F d, Y}
StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week
Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation…{post_date: F d, Y}
Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine
Mayo Clinic News Network: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians…{post_date: F d, Y}
Cardiology’s AI Moment: Anumana’s Top Insights from ACC.25
#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…{post_date: F d, Y}


